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S332 Poster Session IIcells in 15 assays. BM chimerism was at least 10% lower than PB,
M or T cell chimerism in 9/62 assays while PB chimerism was at
least 10% lower than BM chimerism twice. Engraftment (.90%
donor chimerism) occurred in at least one cell line in 124 of 140
pts. The vast majority of pts achieved this by day 60 post-SCT.
28 pts subsequently lost full chimerism; 25 in association with dis-
ease (dx) progression, 3 without progression. 33 pts had dx progres-
sion and/or died without losing full donor chimerism. 3 pts
achieved only myeloid donor chimerism; all are alive without dx
progression. 4 pts had testing but did not report results. With a me-
dian follow up of 12 mos, 85 pts are alive, 56 without dx progres-
sion and with full donor chimerism. Chimerism is commonly
performed following RIC regimens but practices vary widely even
within centers and individual pts. Although loss of donor chime-
rism is most commonly related to dx progression, maintenance of
chimerism does not exclude dx progression, bringing into question
the role of serial monitoring. Outside of a research protocol, for pts
receiving IV busulfan-based RIC, chimerism at a single time point
(d60) to confirm engraftment with no further routine testing
would be cost effective.Table 1. Patient Characteristics
Characteristics All FLT3/ITD 2 FLT3/ITD +
Patients: (n 5 ) 75 59 (78.7%) 16 (21.3%)
Age: (median in years) 49 47.9 50.6
Gender:
Female: 38 (50.7%) 30 8
Male: 37 (49.3%) 29 8
WBC at diagnosis: (median) 15 30.9 34.0
Karyotype:
Normal: 36 (48%) 24 12
Abnormal: 37 (49.3%) 33 4
Unknown: 2 (2.6%) 2 0
Conditioning Regimen:
Myeloablative: 42 (56%) 31 11
Reduced Intensity Conditioning: 33 (44%) 28 5
Donor Type:
Matched Related: 35 (46.7%) 29 6
Matched Unrelated: 29 (38.7%) 24 5
Umbilical Cord: 7 (9.3%) 4 3
Haploidentical: 4 (5.3%) 2 2
Stem Cell Source:
PBSCT: 55 (73.3%) 45 10
Bone Marrow: 13 (17.4%) 10 3
Umbilical Cord: 7 (9.3%) 4 3
GVHD prophylaxis:
CSA/MTX: 39 (52%) 31 8
CSA/MMF: 25 (33.3%) 22 3
FK/MMF: 8 (10.7%) 5 3
Other: 3 (4%) 1 2
Use of Thymoglobulin:
Yes: 18 (24%) 13 5
No: 57 (76%) 46 11
Graft Failure:
Yes: 2 (2.5%) 1 1
No: 73 (97.5%) 58 15
Relapsed:
Yes: 21 (28%) 13 (22%) 8 (50%)
No: 54 (72%) 46 (78%) 8 (50%)
Alive:
Yes: 45 (60%) 35 (59.3%) 10 (63%)
No: 30 (40%) 24 (40.7%) 6 (37%)
Abbreviations: CSA indicates cyclosporine; MTX, methotrexate; MMF,
Mycofenolate Mofetil; FK, FK 507; PBSCT, peripheral blood stem cell
transplant.345
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Background: High fever and/or rash prior to neutrophil engraft-
ment is frequently observed after umbilical cord blood transplanta-
tion (UCBT) and is called pre-engraftment syndrome (PES). Few
studies have evaluated risk factors and treatment response for PES.
Therefore, we retrospectively characterized PES in 57 consecutive
engrafted patients (. 5 12 years old) who received myeloablative
dual UCBT.
Methods: Patients received 2 UCB grafts that were at least 4 of 6
HLA-matched with the recipient. All patients received TBI (. 5
13.2Gy)-based myeloablative conditioning. Tacrolimus (Tac)
(n 5 35) or cyclosporine (CyA) (n 5 22) combined with mycophe-
nolate mofetil was used as a GVHD prophylaxis. CyA was more
commonly used in patients receiving a more intensive conditioning
regimen containing cyclophosphamide. PES was defined as the
presence of either non-infectious fever (. 5 38.5C) and/or rash
prior to or on the day of neutrophil engraftment. The incidence
of PES and overall survival (OS) rate was estimated using the Ka-
plan-Meier method. Incidence of acute GVHD (aGVHD) was es-
timated using the cumulative incidence method. Factors with
p \0.20 in the univariate analysis were used in the multivariate
model.
Results: Median age of patients was 28 (range 12-58) years. The
median combined total nucleated cell dose was 4.8 (range, 2.8-
10.1) x 107/kg. The incidence (95% CI) of PES, grades II-IV
and III-IV aGVHD were 0.77 (0.63-0.86), 0.60 (0.46-0.71), and
0.32 (0.20-0.44), respectively. Multivariate analysis showed that
the use of CyA was the only significant variable associated with
PES (CyA vs. Tac; HR 3.25, p 5 0.003). The use of CyA was
also a significant variable for grade III-IV aGVHD (HR 3.02,
p 5 0.020). Twenty-four of 44 patients with PES were treated
with . 5 1 mg/kg of methylprednisolone or prednisone, which re-
sulted in complete and partial response at day 7 in 10 and 14 pa-
tients, respectively. Acute GVHD developed in 7 of 20 patients
who did not receive systemic treatment for PES (grades II in 3
and grades III-IV aGVHD in 4). Although OS in the Tac group
tended to be higher than in the CyA group, there was no statistical
difference between the two group (p 5 0.102).
Conclusion:GVHD prophylaxis with CyA vs. Tac was a risk factor
for both PES and grades III-IV aGVHD after myeloablative dual
UCBT in our cohort. The impact of GVHD prophylaxis (CyA vs.
Tac) in UCBT will need to be confirmed in a prospective trial
with a uniform conditioning regimen.346
ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3/ITD POSITIVE
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Objective: Fms-Like Tyrosine kinase 3/Internal Tandem Duplica-
tion (FLT3/ITD) mutation in patients with acute myeloid leukemia
(AML) is associated with shorter disease free survival (DFS) and
overall survival (OS). Although evidence from prospective trials is
lacking, allogeneic stem cell transplantation (allo-SCT) is often con-
sidered in patients with FLT3/ITD+ AML in first complete remis-
sion (CR1). Prognostic significance of FLT3/ITD mutation
compared to other conventional prognostic markers in patients re-
ceiving allo-SCT in AML-CR1 is unknown.
Methods: 79 consecutive patients with AML in CR1 received allo-
SCT between June 2005 and May 2011 at Vanderbilt University
Medical Center. 4 patients with unknown FLT3/ITD status were
excluded. The prognostic impact of FLT3/ITD mutation was eval-
uated in the context of other clinical prognostic and genetic risk fac-
tors.
Results: FLT3/ITDmutation was present in 16 (21%) of the 75 pa-
tients who underwent allo-SCT in CR1. There were no significant
differences in age, WBC at diagnosis, or transplant characteristics
